Plain-English translation of NCT06203873 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether closing a small hole in the heart (called a patent foramen ovale or PFO) can help reduce severe migraines. The study compares two different closure devices: the MemoSorb biodegradable occluder, which dissolves over time, and traditional metal occluders, which stay in place permanently. Researchers believe that closing this hole may improve migraine symptoms in people whose condition hasn't responded adequately to other treatments.
Some people with severe migraines have a small opening in their heart that may be contributing to their headaches. While closing this hole has shown promise in reducing migraines, some patients experience worsening symptoms after receiving metal devices, possibly due to the permanent implant. This trial is testing whether a biodegradable device might offer migraine relief with fewer side effects since it dissolves over time rather than remaining in the body permanently.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would be randomly assigned to receive either the biodegradable or metal closure device through a minimally invasive heart procedure. You would then return for follow-up appointments to track how your migraines respond to the treatment and to monitor your recovery. The trial will compare how well each device reduces migraine frequency and severity over time.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China